Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals-Reference-Cited by-同舟云学术

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Published:2019-10 Issue:10 Volume:30 Page:1647-1652
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kurzrock R.,Gurski L.A.,Carlson R.W.,Ettinger D.S.,Horwitz S.M.,Kumar S.K.,Million L.,von Mehren M.,Benson A.B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz232/30076098/mdz232.pdf

Reference32 articles.

1. Prevalence of off-label use of oral oncolytics at a community cancer center;Kalis;J Oncol Pract,2015

2. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists;Conti;J Clin Oncol,2013

3. Off-label use of oncology drugs: too much, too little, or just right?;Burstein;J Natl Compr Canc Netw,2013

4. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study;Wagner;BMJ,2018

5. Randomized phase 2 trial of two different doses of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib;Kumar;Blood,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients;Cell Reports Medicine;2024-03

2. Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016–2021: An observational study;PLOS Medicine;2023-12-12

3. Efficacy of Off-Label Use of Anticancer Drugs in Oncology;Creative surgery and oncology;2023-06-30

4. Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 153,122 U.S. patients;2023-01-18

5. Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies;In Vivo;2023